Loading...
Acceptance and Commitment Therapy Preceded by Attention Bias Modification on Residual Symptoms in Depression: A 12-Month Follow-Up
Østergaard, Tom Lundgren, Tobias Rosendahl, Ingvar Zettle, Robert D. Jonassen, Rune Harmer, Catherine J. Stiles, Tore C. Landrø, Nils I. Haaland, Vegard Øksendal
Østergaard, Tom
Lundgren, Tobias
Rosendahl, Ingvar
Zettle, Robert D.
Jonassen, Rune
Harmer, Catherine J.
Stiles, Tore C.
Landrø, Nils I.
Haaland, Vegard Øksendal
Citations
Altmetric:
Files
Other Names
Location
Time Period
Advisors
Original Date
Digitization Date
Issue Date
2019-08-29
Type
Article
Genre
Keywords
Acceptance and commitment therapy,Attentional bias modification,Combined treatment,Depression,Residual symptoms,Research Subject Categories::SOCIAL SCIENCES::Social sciences::Psychology
Subjects (LCSH)
Citation
Østergaard T, Lundgren T, Rosendahl I, Zettle RD, Jonassen R, Harmer CJ, Stiles TC, Landrø NI and Haaland VØ (2019) Acceptance and Commitment Therapy Preceded by Attention Bias Modification on Residual Symptoms in Depression: A 12-Month Follow-Up. Front. Psychol. 10:1995. doi: 10.3389/fpsyg.2019.01995
Abstract
Depression is a highly recurrent disorder with limited treatment alternatives for reducing
risk of subsequent episodes. Acceptance and commitment therapy (ACT) and attention
bias modification (ABM) separately have shown some promise in reducing depressive
symptoms. This study investigates (a) if group-based ACT had a greater impact in
reducing residual symptoms of depression over a 12-month follow-up than a control
condition, and (b) if preceding ACT with ABM produced added benefits. This multisite
study consisted of two phases. In phase 1, participants with a history of depression,
currently in remission (N = 244), were randomized to either receive 14 days of ABM or
a control condition. In phase 2, a quasi- experimental design was adopted, and only
phase-1 participants from the Sørlandet site (N = 124) next received an 8-week groupbased
ACT intervention. Self-reported and clinician-rated depression symptoms were
assessed at baseline, immediately after phase 1 and at 1, 2, 6, and 12 months after the
conclusion of phase 1. At 12-month follow-up, participants who received ACT exhibited
fewer self-reported and clinician-rated depressive symptoms. There were no significant
differences between ACT groups preceded by ABM or a control condition. There
were no significant differences between ACT groups preceded by ABM or a control
condition. Group-based ACT successfully decreased residual symptoms in depression
over 12 months, suggesting some promise in preventing relapse.
Table of Contents
Description
Open Access.
Publisher
Frontiers Media
Journal
Frontiers in Psychology
Book Title
Series
Digital Collection
Finding Aid URL
Use and Reproduction
Archival Collection
PubMed ID
DOI
ISSN
1664-1078